July 30 (Reuters) – British consumer health company Haleon posted second-quarter organic sales growth of 3.1% on Thursday, in line with estimates, driven by strong demand for its oral health products and accelerating growth in North America, its largest market.
While Haleon has been boosting U.S. sales through expanded distribution and sharper shelf resets, a weak flu season and a pullback in discretionary purchases, such as smoking alternatives, continue to weigh on its performance.
The company also reaffirmed its 2026 forecast for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Sherry Jacob-Phillips)
